Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents

7Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.

Abstract

Introduction: Multiple myeloma (MM) is a malignancy of plasma cells with characteristic bone disease. Despite recent great strides achieved in MM treatment owing to the implementation of new anti-MM agents, MM is still incurable and bone destruction remains a serious unmet issue in patients with MM. Approach: In this review, we will summarize and discuss the mechanisms of the formation of bone disease in MM and the available preclinical and clinical evidence on the treatment for MM bone disease. Conclusions: MM cells produce a variety of cytokines to stimulate receptor activator of nuclear factor-κB ligand-mediated osteoclastogenesis and suppress osteoblastic differentiation from bone marrow stromal cells, leading to extensive bone destruction with rapid loss of bone. MM cells alter the microenvironment through bone destruction where they colonize, which in turn favors tumor growth and survival, thereby forming a vicious cycle between tumor progression and bone destruction. Denosumab or zoledronic acid is currently recommended to be administered at the start of treatment in newly diagnosed patients with MM with bone disease. Proteasome inhibitors and the anti-CD38 monoclonal antibody daratumumab have been demonstrated to exert bone-modifying activity in responders. Besides their anti-tumor activity, the effects of new anti-MM agents on bone metabolism should be more precisely analyzed in patients with MM. Because prognosis in patients with MM has been significantly improved owing to the implementation of new agents, the therapeutic impact of bone-modifying agents should be re-estimated in the era of these new agents.

References Powered by Scopus

The Role of the Wnt-Signaling Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple Myeloma

1341Citations
N/AReaders
Get full text

Denosumab in postmenopausal women with low bone mineral density

1046Citations
N/AReaders
Get full text

Sclerostin Is an Osteocyte-expressed Negative Regulator of Bone Formation, but Not a Classical BMP Antagonist

740Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Adipocytes and metabolism: Contributions to multiple myeloma

2Citations
N/AReaders
Get full text

Efficacy and safety of daratumumab in the treatment of relapsed/refractory multiple myeloma: A meta-analysis of randomized controlled trials

2Citations
N/AReaders
Get full text

Mechanistic insights into bone destruction in multiple myeloma: Cellular and molecular perspectives

0Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Teramachi, J., Miki, H., Nakamura, S., Hiasa, M., Harada, T., & Abe, M. (2023, May 1). Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents. Journal of Bone and Mineral Metabolism. Springer. https://doi.org/10.1007/s00774-023-01403-4

Readers over time

‘23‘24‘250481216

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 6

60%

Researcher 4

40%

Readers' Discipline

Tooltip

Medicine and Dentistry 9

82%

Biochemistry, Genetics and Molecular Bi... 1

9%

Immunology and Microbiology 1

9%

Save time finding and organizing research with Mendeley

Sign up for free
0